GMED vs. STE, PODD, BAX, HOLX, MASI, TFX, ITGR, ATEC, ATRC, and IART
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), AtriCure (ATRC), and Integra LifeSciences (IART). These companies are all part of the "health care equipment" industry.
Globus Medical vs. Its Competitors
Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, STERIS had 1 more articles in the media than Globus Medical. MarketBeat recorded 11 mentions for STERIS and 10 mentions for Globus Medical. STERIS's average media sentiment score of 1.42 beat Globus Medical's score of 1.16 indicating that STERIS is being referred to more favorably in the news media.
95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 18.5% of Globus Medical shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
STERIS has higher revenue and earnings than Globus Medical. STERIS is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Globus Medical has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Globus Medical currently has a consensus target price of $94.00, indicating a potential upside of 64.65%. STERIS has a consensus target price of $263.83, indicating a potential upside of 15.76%. Given Globus Medical's higher possible upside, research analysts plainly believe Globus Medical is more favorable than STERIS.
STERIS has a net margin of 11.26% compared to Globus Medical's net margin of 7.39%. STERIS's return on equity of 14.21% beat Globus Medical's return on equity.
Summary
STERIS beats Globus Medical on 10 of the 16 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
This page (NYSE:GMED) was last updated on 7/12/2025 by MarketBeat.com Staff
